The Thyroid Axis 'Setpoints' are Significantly Altered After Long-Term Suppressive LT4 Therapy

Authors

F. A. Verburg^{1,2}, U. Mäder³, I. Grelle¹, T. J. Visser⁴, R. P. Peeters⁴, J. W. A. Smit⁵, C. Reiners¹

Affiliations

¹ Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany

² Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany

³ Comprehensive Cancer Center, University of Würzburg, Würzburg, Germany

⁴ Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

⁵ Department of Internal Medicine, University Medical Center St. Radboud, Nijmegen, The Netherlands

Key words

- thyroid cancer
- TSH suppression
- levothyroxine
- pituitary

Abstract

The aim of the study was to investigate the changes in the thyroid axis setpoint after long-term suppressive levothyroxine therapy for differentiated thyroid carcinoma and the resulting changes in levothyroxine requirement. Ninety-nine differentiated thyroid cancer patients were reviewed. All patients had at least one known TSH-level ≥ 0.01 mU/l (lower detection limit) and < 1.0 mU/l within 2 years of initial treatment (time 1) and had at least one TSH-value ≥ 0.01 mU/l and < 1.0 mU/l after continuous LT4 therapy for a minimum of 5 years (time 2).

At time 2 the mean LT4 dosage/kg body weight, TSH, FT3, and FT4 levels were significantly lower than at time 1, while body weight was higher. At

time 2, the FT3/FT4 ratio rate had dropped significantly ($p < 0.001$). At time 1, patients would require $2.96 \mu\text{g/kg}$ body weight to reach total TSH suppression. The dose of levothyroxine/kg required for suppression can be lowered by about $0.05 \mu\text{g/kg}$ body weight for each year of suppressive therapy. After a median of 12.7 years of continuous suppressive levothyroxine therapy, patients would require $2.25 \mu\text{g/kg}$ body weight (-23.5%) to reach total TSH-suppression. At least part of this reduction was independent of aging. As a result of changes in thyroid hormone metabolism and thyroid axis setpoint, long-term TSH-suppressive therapy contributes to a reduction in the dosage of levothyroxine per kilogram body weight required for full TSH suppression over time.

received 17.02.2014

accepted 24.04.2014

Bibliography

DOI <http://dx.doi.org/10.1055/s-0034-1375678>

Published online:

May 27, 2014

Horm Metab Res 2014;

46: 794–799

© Georg Thieme Verlag KG

Stuttgart · New York

ISSN 0018-5043

Correspondence

F. A. Verburg, MD, PhD

Department of Nuclear Medicine

RWTH Aachen University Hospital

Pauwelsstrasse 30

52074 Aachen

Germany

Tel.: +49/241/8036 619

Fax: +49/241/8082 520

fverburg@ukaachen.de

Introduction

At least in high-risk differentiated thyroid carcinoma (DTC) patients, levothyroxine (LT4) replacement therapy in TSH-suppressive dosages is still a standard component of treatment after total thyroidectomy and radioiodine ablation of thyroid remnants [1,2]. Formerly, many low-risk patients were treated with TSH-suppressive LT4 therapy as well.

When properly monitored it is possible to titrate the LT4 dosage to a level where TSH-levels are suppressed but no clinical symptoms of hyperthyroidism are reported by patients. Nonetheless, several long-term side-effects of this long-term iatrogenic subclinical hyperthyroidism on major organ systems in the body have been reported, such as a decrease in bone mineral density [3] or a (reversible) diastolic dysfunction [4].

The effects of long-term subclinical hyperthyroidism on the thyroid axis have not been studied extensively. In a recent study, we were

however able to show that in the course of TSH-suppressive LT4 therapy considerable changes in thyroid hormone metabolism occur [5]. This may in turn result in a lower LT4 requirement in order to retain TSH-suppression.

However, it has been known for a long time in the literature that endogenous changes in the thyroid axis occur in healthy individuals over time [6–14]. This is reflected in a decreased LT4 requirement for patients with hypothyroidism with increasing age [15–18]. Therefore, it may also be possible that the phenomena observed after long-term TSH-suppressive therapy are due to increasing age, even though in our previous study we were able to show that most changes found after a short to medium term follow-up were likely not related to increasing age [5].

The aim of the present study therefore was to investigate the changes in thyroid hormone metabolism due to long-term TSH-suppressive therapy for differentiated thyroid carcinoma and the resulting changes in the dose requirements for TSH-suppressive LT4 therapy.

	Time 1	Time 2	p-Value
No. of patients		99	
Histology			
No. of papillary carcinomas		72	
No. of follicular carcinomas		27	
Sex			
No. of male patients		29	
No. of female patients		70	
Time elapsed since diagnosis (years)	0.42 (0.05–1.9)	14.7 (10.1–21.8)	
Age (years)	43.3 (16.4–74.6)	56.2 (29.5–85.3)	
Duration of continuous LT4 therapy in years		12.3 (5.1–21.6)	
Body weight (kg)	75 (47–130)	80 (45–120)	<0.001
Levothyroxine dosage (µg)	200 (100–325)	175 (75–400)	<0.001
Dose of levothyroxine/kg (µg/kg)	2.83 (0.93–4.46)	2.13 (1.20–3.64)	<0.001
ft3 levels (pg/l)	7.3 (4.6–15.5)	5.1 (0.5–9.1)	<0.001
ft4 levels (pg/l)	30.9 (18.4–56.6)	26.5 (14.0–23.2)	<0.001
TSH levels (mU/l)	0.05 (0.01–0.9)	0.08 (0.01–0.7)	0.001

Values are given as median (range)

Table 1 Basic patient characteristics, duration of follow-up, and various laboratory measurements at time 1 and time 2.

Patients and Methods

Database

The Department of Nuclear Medicine of the University of Würzburg, a major referral centre for DTC located in Southern Germany, established the Würzburg Thyroid Cancer Database in 1980. This database allows for larger prospective longitudinal scientific population studies in DTC patients [5,19–24], which are necessary as studies on survival are difficult due to the generally very good prognosis.

Data were recorded by trained medical documentation specialists for each visit, starting with the first visit after initial diagnosis of DTC. Collected data included basic data such as histological subtype, primary tumor diameter, pTNM stage and presence or absence of tumor multicentricity as well as the extent of extrathyroidal invasion. Additionally, thyroid hormone levels, thyroid specific antibody levels as well as thyroglobulin levels were recorded in the database for each visit.

The Würzburg thyroid cancer database, as part of a larger local system of oncologic databases, is updated and analyzed with approval of and continuous monitoring by the local medical ethical committee. At their first visit to our hospital, patients are asked to give written consent for the recording and anonymized analysis of their data.

Patients

From our database which at the end of the study period contained 1 602 patients we selected all 99 patients followed in our hospital who fulfilled all of the following criteria:

- ▶ Total thyroidectomy followed by I-131 ablation for DTC,
- ▶ Suppressive LT4 treatment during follow-up without prescription of other thyroid hormone preparations such as liothyronine,
- ▶ at least one known TSH-level above the lower detection limit of the assay used (see also laboratory analyses) and <1.0 mU/l within 2 years of initial treatment (time 1) and
- ▶ at least one TSH-value above the lower detection limit of the assay used and <1.0 mU/l after a minimum of 5 years of continuous LT4 therapy, calculated from the last time-point TSH levels were >5.0 mU/l (time 2). For this value we took the last available laboratory measurement with TSH was ≥0.01 mU/l for each patient.

Only data recorded between 1987 and 2008 were considered in the present study as before and after this period changes in the clinical assays occurred for which we either no longer have the comparative data, or were unable to perform an in-house comparison.

Patients who only had TSH-levels below the detection limit of the assay at either time 1 and/or time 2 were excluded from this study as undetectable TSH-values could not be used for further calculations (see also analysis). Patients' characteristics are given in ► **Table 1**.

Treatment

All patients included in this study underwent total thyroidectomy followed by I-131 ablation and suppressive LT4 treatment, as was the norm at the time of initial treatment. For clinical purposes TSH-levels ≤0.1 mU/l were considered suppressed.

After about 6 months, LT4 treatment was discontinued for 4 weeks or recombinant human TSH (rhTSH) was administered, after which thyroglobulin measurements and I-131 whole body scintigraphy were performed. If these were unremarkable, a second TSH-stimulated follow-up procedure was performed after an additional 6–12 months. If either thyroglobulin was detectable or whole body scintigraphy showed foci of pathologic I-131 uptake, further course of I-131 therapy was administered. Once 2 consecutive TSH-stimulated follow-up examinations were without pathologic findings, follow-up was carried out by physical examination, measurement of thyroglobulin under TSH-suppressive LT4 treatment and cervical ultrasound every 6 months for 5 years after the last I-131 therapy; thereafter patients returned for follow-up yearly.

Throughout the study period patients were consistently instructed to take the LT4 medication in the morning on an empty stomach, at least half an hour before breakfast. Patients were routinely prescribed preparations from the same manufacturer. During follow-up, the LT4 dose was adjusted based on thyroid hormone levels: if TSH exceeds 0.1 mU/l an increase of the LT4 dose was ordered. However, if patients developed clinical symptoms of hyperthyroidism or if patients' TSH levels were <0.01 in combination with too high levels of free triiodothyronine (FT3), a decrease of the LT4 dose was ordered.

Test	Time period used	Important characteristics
Thyroid Stimulating Hormone		
Interassay CV <5 % for TSH ≥ 0.2 mIU/l; 20 % for TSH = 0.01 mIU/l		
B.R.A.H.M.S.	1987–February 2002	Functional sensitivity: 0.03 mIU/l
Immulite	February 2002–2008	Functional sensitivity: 0.01 mIU/l
Free Triiodothyronine		
Interassay CV 16.4 % across the diagnostic range		
Amerlex	1987–February 2002	Normal range 2.7–7.6 pmol/l
Immulite	February 2002–2008	Normal range 2.7–7.6 pmol/l
Free Thyroxine		
Interassay CV 6.7 % across the diagnostic range		
Amerlex	1987–February 2002	Normal range 11.0–23.0 pmol/l
Immulite	February 2002–2008	Normal range 11.0–23.0 pmol/l

Table 2 Assays used over time for TSH, FT3 and FT4 measurements, with essential characteristics and coefficients of variation (CV).

Laboratory analyses

Throughout the study period blood sampling for measurement of thyroid hormone levels took place in the morning between 8.00 and 11.00 h. Over time, different assays were used for the measurement of various laboratory parameters. An overview of the assays, the time intervals in which they were used, and the most important assay characteristics are given in Table 2. For TSH, we first used a manual radioimmunoassay from B.R.A.H.M.S., formerly also known as Henning, (Hennigsdorf, Germany) and later on the TSH assay on the automated DPC Immulite 2000 (Siemens Healthcare Diagnostics, Eschborn, Germany). As the functional sensitivity until 2002 was 0.03 mIU/l we considered any value smaller than this value to indicate complete TSH suppression. Patients with values below these levels were therefore not included in the study. For the measurement of FT3 and FT4, we first used manual Amerlex radioimmunoassays (Trinity Biotech, Bray co. Wicklow, Ireland), followed by automated assays on the DPC Immulite 2000 assay (Siemens Healthcare Diagnostics, Eschborn, Germany). Extensive day-to-day quality control tests were performed in order to ensure that the values measured were constant and therefore comparable over time; no systematic differences were found between the assays used in the study. External quality control was performed in the form of 3-monthly ring tests of FT3, FT4, and TSH through the “Referenzinstitut für Bioanalytik” (Bonn, Germany).

Statistical analyses

Analyses were performed using Microsoft Excel 2003 (Microsoft corp., Redmond, WA, USA) and SPSS 20.0 (IBM inc., Armonk, NY, USA). p-Values <0.05 were considered to indicate statistical significance. Values at time 1 and time 2 were compared using the non-parametric paired Wilcoxon test. Trend line equations for correlations at time 1 and time 2 were compared using a t-test on the slope and intercept values calculated in linear regression analyses with a dedicated program written by one of the authors (UM). Univariate analysis was performed using linear regression. Subsequent multivariate analysis was performed using linear regression on all variables with p<0.20 in univariate analysis, applying a forward selection model based on likelihood ratios.

Results

Table 1 contains the details of the patients, as well as the various laboratory measurements at time 1 and time 2 and the

Fig. 1 FT4 and FT3 levels at time 1 and time 2 with the trendlines derived from these data points.

results of tests for differences between the 2 time points. As can be seen in Table 1, the mean dosage of LT4 required to achieve adequate TSH suppression decreased between time 1 and time 2, despite the fact that there was an increase in weight in the patients. As a consequence, the mean dose of LT4 dosage/kg bodyweight was also significantly higher at time 1 than at time 2. Also TSH levels, FT3 levels, and FT4 levels were significantly higher at time 1 than at time 2.

Relationship: dose of LT4/kg and FT4 levels

At time 2, the FT4 levels resulting from the ingested LT4 dose per kg bodyweight were significantly higher than at time 1 (median time 1: 11.6 pmol/l/(μg/kg)⁻¹; time 2: 12.5 pmol/l/(μg/kg)⁻¹; p=0.002).

Relationship of FT3 with FT4 levels

The relationship between FT3 and FT4 levels changed significantly over time. The slope of the 2 regression lines seen in Fig. 1 was significantly different at the 2 different time points (p<0.001), although the intercept did not differ significantly (p=0.07). These 2 findings together indicate a change in the T3/T4 conversion ratio. There was no clear relationship between the length of the suppressive interval and the reduction in the FT3/FT4 ratio.

Relationship of TSH with FT4 and FT3 levels

At time 2 there was a significant difference in the relationship between both FT3 levels and TSH levels compared to time 1 and

Fig. 2 TSH-levels vs. **a** the FT3 levels; **b** the FT4 levels; and **c** the dosage of LT4 per kg bodyweight at time 1 and time 2 with the trendlines derived from these data points. The intercept with the x-axis represents the FT3 levels, FT4 levels, and LT4 dosage required for complete TSH suppression, respectively.

FT4 levels and TSH levels; in both relationships the intercept differed significantly ($p < 0.001$ for both) between time 1 and time 2 even though the slope of the relationship did not differ ($p = 0.41$ and $p = 0.21$, respectively) compared to time 1 (○ **Fig. 2a, b**).

TSH suppression

Regression line analysis of the relationship between TSH and the dosage of LT4/kg revealed that at time 1 patients would on average require $2.96 \mu\text{g/kg}$ bodyweight to reach full TSH sup-

Fig. 3 The relationship between the dose of LT4 per kg body weight as a function of age in those aged between 35 and 65 at time 1 and time 2, respectively.

pression (○ **Fig. 2**). This would correspond to mean FT3 levels of 8.0 pmol/l and FT4 levels of 34.3 pmol/l . At time 2 patients would require $2.25 \mu\text{g/kg}$ bodyweight (-23.7% ; $p < 0.001$) to reach total TSH-suppression (○ **Fig. 2c**), corresponding to mean FT3 levels of 5.3 pmol/l (-34% ; $p < 0.001$) and FT4 levels of 27.6 pmol/l (-20% ; $p < 0.001$). This drop in required dose of LT4/kg was highly significant ($p < 0.001$).

There was a significant negative relationship between the duration of continuous TSH suppressive therapy and the reduction in dosage of LT4/kg needed for suppression at time 2 (Spearman's test, $p < 0.001$); the daily LT4 dose required for TSH-suppression on average can be lowered by $0.05 \mu\text{g/kg}$ bodyweight for each year of TSH-suppressive LT4 therapy that has passed.

In order to explain the change in the dose of LT4/kg a linear regression was performed. In univariate analysis the dose of LT4/kg at time 1 ($p < 0.001$), sex ($p = 0.022$) and the duration of the suppressive LT4 therapy until time 2 ($p = 0.006$) were statistically significantly related to the change in LT4/kg. Age at the time of diagnosis was not significantly related to the change in LT4/kg ($p = 0.06$) in univariate analysis. However, in multivariate analysis with a forward selection model based on likelihood ratios the dose of LT4/kg at time 1 and age at diagnosis turned out to be independent determinants of the change in the dose of LT4/kg; higher dosages at time 1 as well as higher age at time 1 allowed a greater dosage reduction by the time 2 was reached.

Influence of age

It is known from literature that endogenous thyroid hormone production as well as the levothyroxine requirement for hypothyroidism decreases with increasing age. As the patients in the present study have aged considerably over the course of the more than 2 decades of the present study and the age at time 1 was identified as a determinant of the decrease in the dose of LT4/kg, one could argue that part of the effect in the present study can be explained by increased age. In order to exclude this possibility we analyzed the relationship between age and the required dose of LT4/kg in patients who were between 35 and 65 at time 1 ($n = 71$) and time 2 ($n = 69$), respectively. It can be seen from ○ **Fig. 3** that at both time points there is a significant negative correlation between age and the dose of LT4/kg (time 1:

Spearman's test, $p=0.002$; time 2 Spearman's test, $p=0.023$), of which the slope is not different between time 1 and time 2 ($p=0.18$). However, there is a significant downward shift in this relationship (intercepts significantly different, $p<0.001$), with as a result that due to TSH suppressive therapy, the dose of LT4/kg required for TSH suppressive therapy in relation to age is higher at time 1 than at time 2 for the age span analyzed here.

Discussion

Although literature has a considerable body of evidence on the physiologic effects of long-term subclinical hyperthyroidism on various organ systems [4,25], the effects on thyroid hormone metabolism itself have been poorly documented. Data obtained in a previous study suggested that TSH-suppressive therapy in patients likely leads to a downregulation of deiodinase subtypes 1 and 2 (D1 and D2) and an upregulation of deiodinase subtype 3 (D3) [5]. In this study we can confirm our earlier laboratory data in a larger group of clinical patients followed over a long time. Furthermore in the present study we clearly show that there is a change in the set point of the thyroid axis: the LT4 requirement per kg bodyweight required for TSH suppression is clearly reduced; in this process both age-related and age-independent phenomena appear to play a role.

The present data indicate that after long-term suppressive LT4 therapy, TSH suppression requires significantly lower levels of FT3 and FT4 in peripheral blood, which in turn results in a significantly reduced required dose of LT4/kg. The physiologic basis of this phenomenon is unclear as well. In multivariate analysis an initially higher age and a larger dose of LT4/kg allowed for a greater reduction, hinting at a complex, multifactorial regulation process, especially when considering that it has been long-established that in older patients thyroid hormone production is decreased and TSH levels may be physiologically higher [6–14]. This is in contrast with the present study, where TSH levels were lower in older patients in spite of reduced LT4 doses after long-term TSH suppressive therapy. When comparing people of similar age at time 1 with patients at that age at time 2 it is remarkable to see the downward shift in the relationship between the LT4 requirement and age, clearly hinting at an additional role for TSH-suppressive therapy related effects on thyroid hormone metabolism which contribute to a possible reduction of the LT4 dose over time.

Aging has also been described to influence the relationship between thyroid hormone levels and TSH-levels in peripheral blood in a rat model. In this model it was found that in aging rats central D2 expression was elevated, resulting in a preserved local FT3 level even when peripheral levels were lower than in younger rats [26]. Although this remains to be confirmed for humans, it is conceivable that a similar role may play a role in the present findings.

The present study remains a retrospective observational study of a fraction of all the patients treated in our hospital, with all the drawbacks and limitations that come with such a study design. A large number of patients who continuously had TSH-levels below the detection limit were not analyzed in this study; it is quite possible that the phenomena described here occur to a different degree in such patients but this is impossible to assess accurately. Another limitation of the present study is the long time-span over which the data have been acquired; assays used in clinical practice were changed during the period of the study

and measurements were performed using kits from many different lots. Even though extensive quality controls were in place to ascertain that the values found were comparable between assays, small influences of the use of different assays cannot be ruled out completely. A further weakness of the present study is that we have no control group treated with replacement, rather than suppressive, doses of LT4, for the same time period; therefore we cannot yet be certain that the effect found in the present study is solely attributable to suppressive LT4 therapy and our results therefore have to be treated as indicative.

Nonetheless, the effects found in the present study may significantly impact daily practice. Even though the paradigm of life-long LT4 suppression in all DTC patients has been relinquished in several recent guidelines and consensus papers [1,2,27], it still remains a cornerstone of treatment in high-risk patients. A lot of high-risk patients, however, tend to be elderly who are especially at risk of the consequences of subclinical hyperthyroidism. For example, it has been described that long-term subclinical hyperthyroidism leads to a (reversible) diastolic cardiac dysfunction [4] or osteoporosis. In view of such adverse effects it is desirable to keep the LT4 dose as low as possible throughout life. The present study shows that there is likely room for a periodic lowering of the LT4 dose with increasing age and long-term duration of TSH suppressive therapy.

Conclusion

Next to the known age-related reduction in levothyroxine requirement, long-term TSH-suppressive therapy contributed to a reduction in the dosage of LT4 per kilogram bodyweight required for full TSH suppression as a result of changes in thyroid hormone metabolism and the thyroid axis set point, which is likely due to a complex series of interacting changes due to both aging and TSH-suppressive therapy.

Conflict of Interest

The authors declare that they have no conflicts of interest in the authorship or publication of this contribution.

References

- Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009; 19: 1167–1214
- Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 2006; 154: 787–803
- Heemstra KA, van der Deure WM, Peeters RP, Hamdy NA, Stokkel MP, Corssmit EP, Romijn JA, Visser TJ, Smit JW. Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. *Eur J Endocrinol* 2008; 159: 69–76
- Smit JW, Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bleeker GB, Holman ER, van der Wall EE, Romijn JA, Bax JJ. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. *J Clin Endocrinol Metab* 2005; 90: 6041–6047
- Verburg FA, Smit JW, Grelle I, Visser TJ, Peeters RP, Reiniers C. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. *Clin Endocrinol (Oxf)* 2012; 76: 577–581

- 6 van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. *J Clin Endocrinol Metab* 2005; 90: 6403–6409
- 7 Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A. Complex alteration of thyroid function in healthy centenarians. *J Clin Endocrinol Metab* 1993; 77: 1130–1134
- 8 Chiovato L, Mariotti S, Pinchera A. Thyroid diseases in the elderly. *Baillieres Clin Endocrinol Metab* 1997; 11: 251–270
- 9 van Coevorden A, Laurent E, Decoster C, Kerkhofs M, Neve P, Van Cauter E, Mockel J. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. *J Clin Endocrinol Metab* 1989; 69: 177–185
- 10 van Coevorden A, Mockel J, Laurent E, Kerkhofs M, L'Hermite-Baleriaux M, Decoster C, Neve P, Van Cauter E. Neuroendocrine rhythms and sleep in aging men. *Am J Physiol* 1991; 260: E651–E661
- 11 Barreca T, Franceschini R, Messina V, Bottaro L, Rolandi E. 24-hour thyroid-stimulating hormone secretory pattern in elderly men. *Gerontology* 1985; 31: 119–123
- 12 Herrmann J, Heinen E, Kroll HJ, Rudorff KH, Kruskemper HL. Thyroid function and thyroid hormone metabolism in elderly people. Low T3-syndrome in old age? *Klin Wochenschr* 1981; 59: 315–323
- 13 Gregerman RI, Gaffney GW, Shock NW, Crowder SE. Thyroxine turnover in euthyroid man with special reference to changes with age. *J Clin Invest* 1962; 41: 2065–2074
- 14 Inada M, Koshiyama K, Torizuka K, Akagi H, Miyake T. Clinical studies on the metabolism of 131-I-labeled L-thyroxine. *J Clin Endocrinol Metab* 1964; 24: 775–784
- 15 Davis PJ, Davis FB. Hypothyroidism in the elderly. *Compr Ther* 1984; 10: 17–23
- 16 Davis FB, LaMantia RS, Spaulding SW, Wehmann RE, Davis PJ. Estimation of a physiologic replacement dose of levothyroxine in elderly patients with hypothyroidism. *Arch Intern Med* 1984; 144: 1752–1754
- 17 Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. *Am J Med* 1983; 75: 206–209
- 18 Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. *Ann Intern Med* 1982; 96: 53–55
- 19 Verburg FA, Mader U, Luster M, Reiners C. Primary tumor diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2008; 71: 291–297
- 20 Verburg FA, Mader U, Tanase K, Thies ED, Diessl S, Buck AK, Luster M, Reiners C. Life Expectancy Is Reduced in Differentiated Thyroid Cancer Patients ≥45 Years Old with Extensive Local Tumor Invasion, Lateral Lymph Node, or Distant Metastases at Diagnosis and Normal in All Other DTC Patients. *J Clin Endocrinol Metab* 2013; 98: 172–180
- 21 Verburg FA, Mader U, Luster M, Reiners C. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. *Eur J Endocrinol* 2009; 160: 619–624
- 22 Verburg FA, Mader U, Kruitwagen CL, Luster M, Reiners C. A comparison of prognostic classification systems for differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2010; 72: 830–838
- 23 Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2010; 37: 276–283
- 24 Diessl S, Holzberger B, Mader U, Grelle I, Smit JW, Buck AK, Reiners C, Verburg FA. Impact of moderate vs. stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2012; 76: 586–592
- 25 Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. *Thyroid* 2006; 16: 583–591
- 26 Christoffolete MA, Ribeiro R, Singru P, Fekete C, da Silva WS, Gordon DF, Huang SA, Crescenzi A, Harney JW, Ridgway EC, Larsen PR, Lechan RM, Bianco AC. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. *Endocrinology* 2006; 147: 1735–1743
- 27 Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; 21 (Suppl 5): v214–v219